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Abstract Chemokines play a key role in modulating leukocyte
functions at sites of inflammation. To assess chondrocyte
contribution to the chemotactic environment of inflamed joints
the intracellular content of CC and CXC chemokines was
investigated. IL-8, GROK, MCP-1, RANTES, MIP-1K and
MIP-1L expression was evaluated by flow cytometric analysis
and RT-PCR in chondrocytes isolated from cartilage specimens
obtained from patients with osteoarthritis and rheumatoid
arthritis and multiorgan donors as normal controls. All the
chemokines except RANTES were found in normal chondro-
cytes, with different degrees of staining intensity. In osteoar-
thritis and rheumatoid arthritis patients, an enhancement of
IL-8, GROK, MIP-1K and MIP-1L was observed.
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1. Introduction
The role of chemokines as second step mediators of local
in£ammation has recently gained increasing evidence [1,2].
The ability of chondrocytes to express in vitro some members
of this expanding family of molecules has been reported.
These cells release interleukin-8 (IL-8) when stimulated with
interleukin-1 (IL-1), tumor necrosis factor K (TNFK), or lip-
opolysaccharide (LPS) [3^5]. IL-8 was localised in vivo in
cartilage derived from rheumatoid arthritis (RA) and osteo-
arthritis (OA) patients with a distribution resulting in a che-
motactic gradient favouring localisation of neutrophils to the
joint lumen: an average 20% positive cells in joint surface in
both diseases [6]. IL-1L induction of GROK in normal chon-
drocytes was described by Recklies and Golds [5] who found
that these cells produce all the members of the GRO family
when cultured in monolayer, while only mRNA for GROQ
was detectable in cartilage explants.
These data were recently con¢rmed by Heller et al. [7] who,
using a cDNA microarray of human proin£ammatory genes,
found in primary chondrocytes low constitutive levels of
RANTES and a strong upregulation of IL-8 and GROK
upon activation with phorbol myristate acetate and IL-1.
Among the CC chemokines, the induction of MCP-1 by IL-
1, TNFK, LPS, platelet-derived growth factor and transform-
ing growth factor L in cultured chondrocytes and in organ
cultures was reported by Villiger et al. [8]. In addition, the
temporal kinetics and zonal distribution details of IL-1 e¡ects
across the various cartilage layers were investigated by in situ
hybridisation on cartilage organ cultures.
Overall, most of these reports are focused on the expression
of the prototypic members of the CC and CXC chemokine
subfamilies upon stimulation with proin£ammatory activa-
tors, and a wide analysis of the chondrocyte chemokine pro¢le
in vivo is lacking.
The aim of the present study was therefore to investigate
intracellular chemokine expression in freshly isolated chon-
drocytes derived from healthy subjects and patients with OA
and RA, to disclose a disease-related chemokine pro¢le in
vivo. Freshly isolated chondrocytes were used, to avoid the
possibility of altering the phenotypic pattern of proteins in
cultured cells. The staining of the cytoplasmic chemokines
was performed in suspension, followed by £ow cytometric
analysis, thus exploiting the great analysis potential of this
technology and the superior sensitivity of immuno£uorescence
particularly when performed on intact cells. A parallel assess-
ment of the expression of these chemokines at the RNA level
was also undertaken, by RT-PCR.
Chondrocytes have been repeatedly likened to cells of the
monocyte-macrophage lineage both at the functional [9,10]
and at the phenotypic level [11]. We included in our analysis
several chemokines produced by monocytes upon stimulation,
belonging to either the CXC (IL-8 and GROK) or the CC
family (MCP-1, RANTES, MIP-1K, MIP-1L).
2. Materials and methods
2.1. Cell isolation
Chondrocytes were isolated from specimens obtained from eight
OA patients (mean age 62.5, range 23^76) and ¢ve RA patients
(mean age 63.4, range 53^74) undergoing joint replacement and
from cartilage obtained immediately post mortem from two healthy
multiorgan donors (age 24 and 57). Informed consent from the pa-
tients and approval by the ethical committee of the hospital were
obtained.
Cells were isolated by sequential enzymatic digestion as previously
described [12].
After isolation, cell count and viability were assessed and the cells
were ¢xed with ¢ltered, freshly prepared 4% paraformaldehyde in PBS
for 2 h at room temperature (RT), then washed twice with PBS and
kept at 4‡C in DEPC-treated PBS at a concentration of 4U106/ml
until used.
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2.2. Chemokine staining and £ow cytometric analysis
The monoclonal antibodies (mAbs) against human chemokines
were: anti-IL-8 (PeproTech, Rocky Hill, NJ, USA), anti-GROK
(RpD Systems, Minneapolis, MN, USA), anti-MCP-1 (PeproTech),
anti-RANTES (RpD Systems), anti-MIP-1K (RpD Systems) and
anti-MIP-1L (RpD Systems). For labeling experiments 105 cells
were processed in 0.5 ml tubes, washing at 3200Ug between each step.
Aliquots of 25 Wl from cell stock containing this amount of cells
were centrifuged with an equivalent volume of saponin bu¡er (0.1%
saponin and 0.1 M HEPES bu¡er in HBSS). After a permeabilisation
step (10 min at RT soaking in 0.1% saponin and 0.01 M HEPES
bu¡er in HBSS) the cells were pelleted and incubated with 10 Wg/ml
of the various mAbs in saponin bu¡er for 30 min at RT. After wash-
ing with saponin bu¡er, a goat anti-mouse FITC conjugate (Becton
Dickinson, San Jose, CA, USA) at 12.5 Wg/ml was added and incu-
bated for 20 min at RT in the dark. After washing the cells were
analysed on a FACStar Plus cytometer (Becton Dickinson). For com-
parison between experiments, £uorescein quantitative standard beads
(Flow Cytometry Standards, Research Triangle Park, NC, USA) were
used to quantify the £uorescence signal, constructing a standard curve
of £uorescence to represent the log10 of the £uorescence intensity in
molecules of equivalent soluble £uorochrome (MESF) as a function of
the mean channel value. In cases of bimodal distribution of the £uo-
rescence signal, the mean channel value of the more representative
portion of the sample was taken into account. The experimental cal-
ibration curve was y = 0.004x+2.71 (Pearson coe⁄cient = 0.999) ob-
tained from the following data: £uorescence intensity in MESF/
mean channel 0/17.9; 2500/176.5; 6500/270.8; 19 000/395.5; 55 000/
499.4; 150 000/621.3.
2.3. Immunohistochemistry
Cryostat sections of 5 Wm thick were ¢xed with absolute acetone for
10 min at 4‡C and then air dried. After a rehydration step with 0.1%
saponin in Tris-bu¡ered saline pH 7.4 (TBS), blocking of non-speci¢c
binding was performed by incubating the sections for 30 min in PBS
with 2% bovine serum albumin. All washes between the various steps
were performed in TBS with 0.1% saponin at RT. Anti-chemokine
mAbs were incubated overnight at RT at the following concentra-
tions: 5 Wg/ml (anti-IL-8), 10 Wg/ml (anti-MIP-1K) and 20 Wg/ml
(anti-GROK). After washing a biotinylated goat anti-mouse antiserum
(Kirkegaard and Perry labs, Gaithersburg, MD, USA) at 1.5 Wg/ml
was incubated for 1 h at RT followed by alkaline phosphatase strep-
tavidin conjugate diluted 1:2000 (Boehringer, Mannheim, Germany).
New fuchsin (Dako, Glostrup, Denmark) in the presence of 5 mM
levamisole (Dako) to block endogenous alkaline phosphatase activity,
was used as substrate to detect chemokine positive cells.
2.4. RNA extraction and RT-PCR
Soon after isolation the cells were gently pelleted at 1000Ug at 4‡C
and stored dry at 380‡C until processing.
RNA extraction was done according to the TRIzol protocol (Gibco
BRL, Grand Island, NY, USA) and the extracted RNA was evaluated
with the spectrophotometer for quantity and purity. 1 Wg of each
sample was reverse transcribed for 1 h at 42‡C with 2.5 WM Oligo-
dT and 250 U of MuMLV RNase H3 (Promega, Madison, WI,
USA), according to the manufacturer’s instructions. 50 ng per tube
of the various cDNAs were used in the subsequent RT-PCR per-
formed with 2.5 U Taq with equimolar concentration of Taq Start
antibody (Clontech, Palo Alto, CA, USA) at pH 8.3 and 1.5 mM
magnesium, 200 WM dNTPs and 1 WM concentration for the primers.
The thermocycling pro¢le comprised four cycles at 94‡C 10 s, 56‡C 10
s, 72‡C 10 s and 31 cycles at 90‡C 10 s, 60‡C 10 s, 72‡C 10 s. Primer
sequences were such as to amplify respectively: a 219 bp product for
the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) used as an internal quality standard (upstream primer
corresponding to nt 771^788 and downstream primer complementary
to nt 971^989 of M17851); a 289 bp product for IL-8 (upstream
primer corresponding to nt 771^788 and downstream primer comple-
mentary to nt 971^989 of M17851), a 164 bp product for GROK
(upstream primer corresponding to nt 154^172 and downstream pri-
mer complementary to nt 297^317 of X12510), a 353 bp product for
MCP-1 (upstream primer corresponding to nt 24^47 and downstream
primer complementary to nt 351^377 of X14768), a 275 bp product
for RANTES (upstream primer corresponding to nt 27^48 and down-
stream primer complementary to nt 282^302 of M21121), a 300 bp
product for MIP-1K (upstream primer corresponding to nt 79^97 and
downstream primer complementary to nt 361^379 of M23542) and a
286 bp product for MIP-1L (upstream primer corresponding to nt
106^127 and downstream primer complementary to nt 370^392 of
J04130).
3. Results
3.1. FACS analysis
Chemokines were detected in vivo by intracellular staining
of chondrocytes isolated from eight OA patients, ¢ve RA
patients and two multiorgan donors (MD). Flow cytometric
analysis indicated di¡erential magnitudes of the signal for the
di¡erent chemokines tested, as assessed by evaluation of the
increments over control £uorescence intensity (Fig. 1). It is
interesting to point out that the mean values of £uorescence
increments obtained in the three groups under study were
strictly correlated (Kendall Tau = 0.52, P = 0.006) with the
mean values of corresponding chemokine concentration (ng/
ml) in the supernatant of unstimulated chondrocytes obtained
from the same groups (data not shown, obtained from two
Fig. 1. Indirect immuno£uorescence staining of intracellular chemo-
kines: £uorescence signal of labeled chondrocytes obtained from
multiorgan donors (MD), osteoarthritis patients (OA), and rheuma-
toid arthritis patients (RA). Results, expressed in molecules of
equivalent soluble £uorochrome (MESF), report increments over
basal £uorescence intensity of control cells (cells incubated with the
£uorescein-conjugated goat anti-mouse immunoglobulins) and indi-
cate an enhanced chondrocyte content of IL-8, GROK, MIP-1K and
MIP-1L in OA and RA patients.
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controls, 10 OA and 11 RA cases). OA and RA chondrocytes
showed an enhancement of intracellular content of IL-8,
GROK, MIP-1K and MIP-1L. Chondrocyte chemokine pro-
¢les representative of the two organ donors and of OA pa-
tients are shown in Fig. 2A and Fig. 2B respectively.
It is noteworthy that in one RA case chondrocytes were
nearly devoid of all the chemokines except MIP-1K (Fig. 2C).
3.2. RT-PCR
The overexpression of chemokines in OA and RA com-
pared to normal controls was con¢rmed also in RT-PCR
(Fig. 3), performed in one case for each group.
3.3. Immunohistochemistry
The intense positivity for IL-8 in intact normal cartilage
Fig. 2. Flow cytometric data of intracellular chemokine labeling in chondrocytes derived from an organ donor (A), an osteoarthritis patient (B)
and a rheumatoid arthritis patient (C). Empty pattern: control cells, incubated with the secondary antibody only; solid pattern: cells incubated
with the chemokine-speci¢c monoclonals.
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was con¢rmed also in immunohistochemistry performed in
one MD case, thus excluding the possibility of the £ow cyto-
metric results being an artifact of the isolation process (Fig.
4). Compared to IL-8, signal intensities for GROK and MIP-
1K were lower (data not shown), in agreement with the results
of £ow cytometric analysis (mean values of £uorescence incre-
ments for the two MD: IL-8 = 82 514 MESF, GROK= 16 802
MESF, MIP-1K= 28 916 MESF).
4. Discussion
The present study extensively describes the analysis of
chondrocyte chemokine pro¢le in vivo. The main ¢nding is
that chondrocytes derived from healthy joints store di¡eren-
tial amounts of chemokines in intracellular organelles with no
need for previous stimulation with proin£ammatory cyto-
kines. Chondrocytes could therefore be ready to amplify an
in£ammatory response because they already contain stored
chemokines which can modulate leukocyte responses. The
presence of chemokines in normal cartilage might ful¢l a
physiological role which has yet to be elucidated. In OA
and RA, a strong upregulation may occur, possibly due to
the e¡ect of IL-1 and TNFK. Our data are not in agreement
with the ¢ndings of Recklies and Golds [5] and Deleuran et al.
[6] : Recklies and Golds monitored the de novo synthesis of
IL-8 and of the chemokines of the GRO family in chondro-
cytes and cartilage explants stimulated with IL-1L and re-
ported that when exposed in their natural environment chon-
drocytes express IL-8 mRNA and only the GROQ mRNA
among the GRO family. In contrast we found expression of
GROK in uncultured normal chondrocytes and an enhance-
ment of transcription in the OA and RA patients. Partially
accounting for this discrepancy could be the fact that isolation
of pure RNA from cartilage is di⁄cult, due to the low cell
density and the interfering high glycosaminoglycan content.
Second, we designed GROK primers to amplify a small frag-
ment, comprised of the coding sequence, which leads to a
more successful ampli¢cation than the long fragment used
by Recklies and Golds, taking into account the high rate of
RNA turnover of inducible proteins. To our knowledge the
only report dealing with the in vivo expression of chemokines
in chondrocytes was the work of Deleuran et al. who only
found IL-8 in nearly 20% of super¢cial chondrocytes in OA
and RA patients. Our £ow cytometric and immunohistochem-
istry data show instead that all chondrocytes are positive,
possibly because of the superior sensitivity of immuno£uor-
escence on intact cells and immunohistochemistry coupled
with an avidin-biotin detection over the APAAP technique
[13]. Thus, although at di¡erent levels, all the chemokines
we analysed are present in OA and RA chondrocytes, and
could therefore contribute to the chemotactic environment
of synovial £uid (SF), whose composition may re£ect di¡ering
pathophysiologic mechanisms operational in these diseases.
This could be particularly relevant for osteoarthritis, given
the absent or minor role of synovial tissue in£ammation.
On the other hand, most chemokines have been found at
far higher levels in RA SF compared to OA (GROK [14];
MCP-1 [15]; MIP1K [16]), due to the contribution of the in-
£amed synovial tissue. It has been reported that the combined
action of adhesion molecules, chemokines and chemokine re-
ceptors provides an address code for leukocyte extravasation
and migration into tissue [17]. Therefore, it is conceivable that
the di¡erent cell composition of SF in OA and RA depends
on the di¡erent chemokine composition of the SF itself.
The prominent cell type in RA SF is polymorphonuclear
cells [18] recalled by a chemotactic activity which is accounted
for by IL-8, GROK and ENA78 [14]. Instead, mononuclear
cells (MNC) are prevalent in non-in£ammatory SF, with
Fig. 3. RT-PCR of IL-8, GROK, MCP-1, RANTES, MIP-1K and
MIP-1L starting with 50 ng cDNA from normal chondrocytes
(MD), osteoarthritic chondrocytes (OA) and rheumatoid arthritis
chondrocytes (RA). GAPDH was used as an internal control to en-
sure equal loading between samples. Band intensities indicate an en-
hancement of transcription for most chemokines in OA and RA pa-
tients.
Fig. 4. Immunohistochemistry of a 5 Wm thick normal cartilage
specimen (multiorgan donor): all chondrocytes stained positive for
IL-8 (avidin-biotin technique with streptavidin-alkaline phosphatase,
new fuchsin as substrate and hematoxylin counterstaining). The im-
age was rendered in a grey scale by acquisition with a monochrome
charge-coupled device camera (Sony, Kangawa-ken, Japan). Magni-
¢cation U162.5.
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monocytes being the most prominent cell type [19]. It has been
reported that a relevant fraction of OA SF chemotactic activ-
ity for monocytes and particularly for activated monocytes is
represented by MIP-1L, which is present at a far higher con-
centration compared to RA SF [20]. Our data suggest that
chondrocytes might greatly contribute to MIP-1L concentra-
tion in SF.
The MNC composition of OA and RA SF has been com-
pared by Fort and coworkers [18] : although RA SF presented
a signi¢cantly greater number of cells of all types, some sig-
ni¢cant di¡erences were found in the percentages: CD3+ (T
lymphocytes) and CD4+ (T helper cells) percentages were
higher in RA, while percentages of CD14+ (i.e. macro-
phage/monocytes) and CD16/CD56 (i.e. natural killer cells)
were higher in OA. Other authors [21] have also reported
that the great majority of CD4+ cells are CD45RO+ and
CD45RA3 in both patient groups. Mast cells also seem to
play a relevant role in in£ammation and cartilage breakdown
in OA: mast cell counts [22] and mast cell activation indices
[23] are higher in OA compared with other joint diseases.
Concerning RANTES, the magnitude of the signal for this
cytokine was far lower, but a signi¢cant increase was observed
in some OA and RA patients.
In conclusion, chondrocytes store large amounts of chemo-
tactic factors, which can be further enhanced in some patho-
logical conditions, following exposure to proin£ammatory
cytokines. The same factors lead to release of these chemo-
attractants from the cells to the matrix, as could be the case
for the patient with RA who appeared to be nearly negative
for most chemokines. The proteoglycan-rich matrix, then,
could play a key role in conditioning the release of chemo-
kines into synovial £uid, which can be modulated by di¡er-
ences in their a⁄nity for matrix components [5,8].
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